Skip to main content
. 2022 Feb 25;29:10732748221076682. doi: 10.1177/10732748221076682

Figure 7.

Figure 7.

Patients with FAT1/2/3/4 mutations showed better response to ICIs in Hellmann NSCLC cohort. (A) PFS Kaplan–Meier survival curves comparing the mutant FAT1/2/3/4 with wildtype FAT1/2/3/4. (B) Comparison of BOR rates between mutant FAT1/2/3/4 and wildtype FAT1/2/3/4. (C) Comparison of DCB rates between mutant FAT1/2/3/4 and wildtype FAT1/2/3/4.